নির্দেশনা
Faricimab is a bispecific angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (wet) age-related macular degeneration (nAMD) Diabetic macular edema (DME) Macular edema secondary to retinal vein occlusion (RVO)
Composition
ফার্মাকোলজি
Faricimab is a humanized bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralization of both Ang-2 and vascular endothelial growth factor A (VEGF-A). Ang-2 causes vascular instability by promoting endothelial destabilization, pericyte loss, and pathological angiogenesis, thus potentiating vascular leakage and inflammation. It also sensitizes blood vessels to the activity of VEGF-A resulting in further vascular destabilization. Ang-2 and VEGF-A synergistically increase vascular permeability and stimulate neovascularization. By dual inhibition of Ang-2 and VEGF-A, faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability.
মাত্রা ও সেবনবিধি
General : For intravitreal injection only. VABYSMO must be administered by a qualified physician experienced in intravitreal injections. Each vial should only be used for the treatment of a single eye. Neovascular (wet) age-related macular degeneration (nAMD) : The recommended dose for VABYSMO is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 4 doses, followed by 6 mg (0.05 mL) via intravitreal injection at a dosing interval of up to every 16 weeks (4 months). Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion. Diabetic macular edema (DME) : The recommended dose for VABYSMO is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 4 doses, followed by 6 mg (0.05 mL) via intravitreal injection at intervals of up to every 16 weeks (4 months). Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion. Macular edema secondary to retinal vein occlusion (RVO) : The recommended dose for VABYSMO is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly). Monitoring between the dosing visits should be scheduled based on the patient’s status and at the physician’s discretion.
প্রতিনির্দেশনা
Faricimab is contraindicated in patients with ocular or periocular infections. Faricimab is contraindicated in patients with active intraocular inflammation. Faricimab is contraindicated in patients with known hypersensitivity to faricimab or any of the excipients. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.
পার্শ্ব প্রতিক্রিয়া
গর্ভাবস্থায় ও স্তন্যদানকালে
There are no data from the use of Faricimab in pregnant women. It is not known whether Faricimab is excreted in human breast milk. No studies have been conducted to assess the impact of Faricimabon milk production or its presence in breast milk.